Latest Atritech Inc. Stories
NATICK, Mass., March 3, 2011 /PRNewswire/ -- Boston Scientific Corporation (NYSE: BSX) today announced the completion of its acquisition of Atritech, Inc. of Plymouth, Minnesota. The completion of the transaction follows the signing of a definitive merger agreement announced on January 19, 2011.
NATICK, Mass., Jan. 19, 2011 /PRNewswire/ -- Boston Scientific Corporation (NYSE: BSX) today announced the signing of a definitive merger agreement, under which the Company will acquire Atritech, Inc., a privately held company based in Plymouth, Minnesota.
MINNEAPOLIS, Nov. 2, 2010 /PRNewswire/ -- Atritech, Inc. today announced initial enrollment into its confirmatory study, PREVAIL, comparing the WATCHMANÂ® Left Atrial Appendage Closure Device to long term warfarin therapy in patients with atrial fibrillation.
MINNEAPOLIS, Oct. 1 /PRNewswire/ -- Atritech announces German reimbursement coverage of the left atrial appendage closure procedure in 2011.
MINNEAPOLIS, March 18 /PRNewswire/ -- Atritech, Inc., an emerging medical device company, announced today that it has obtained clarity from the U.S.
An experimental device to treat a common heart problem that can lead to stroke showed promising results in a large clinical study, but carries some risk, according to new research reported on Saturday.
Company scheduled to announce PROTECT AF results on March 28th at ACC. MINNEAPOLIS, March 26 /PRNewswire/ -- Atritech, Inc. a clinical stage medical device company, announced today that it has completed a $30 million round of financing.
MINNEAPOLIS, Feb. 19 /PRNewswire/ -- Atritech, Inc. announced the upcoming presentation of the PROTECT AF trial results comparing the WATCHMAN(R) Left Atrial Appendage (LAA) Closure Device to the current standard of care, warfarin therapy, in patients with non-valvular atrial fibrillation.
MINNEAPOLIS, Aug. 18 /PRNewswire/ -- Atritech, Inc. today announced the filing of its Pre-Market Approval Application (PMA) to the Food and Drug Administration (FDA). The PMA contains the results of the PROTECT AF Clinical Trial which began enrollment in early 2005.
- To say in too many words; to express verbosely.
- To express in too many words: sometimes used reflexively.
- The leading idea or a repeated phrase, as of a song or ballad; the refrain; burden.